Efficacy and Safety of Oral Spironolactone for Women With Acne Vulgaris: A Systematic Review and Meta‐Analysis of Randomized Placebo‐Controlled Trials With Trial Sequential Analysis
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.70411 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Laura Ghanem und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon. Hauptthemen laut MEDLINE: Spironolactone, Acne Vulgaris, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Adult acne vulgaris is a chronic inflammatory skin condition that primarily affects females. Initial management includes topical and oral medications, but important limitations include ineffectiveness, nonadherence, and adverse effects. Spironolactone has shown good results in off‐label acne management.
Aims
We aim to conduct a systematic review and meta‐analysis exploring the safety and efficacy of oral spironolactone for females with acne.
Methods
We searched PubMed, Embase, and Cochrane for randomized controlled trials (RCTs) comparing oral spironolactone in women with acne to placebo. The primary endpoint was the objective assessment of acne improvement. Secondary endpoints included subjective assessment and adverse events. Statistical analysis was performed using Review Manager 5.4. Heterogeneity was assessed with I 2 statistics.
Results
We included 563 patients from 5 RCTs, of which 251 (42.9%) received spironolactone. Objective assessment of acne improvement (OR 6.59; 95% 3.50–12.43; p < 0.00001; I 2 = 0%) was sixfold higher in the spironolactone group compared with placebo. Subjective assessment showed no difference between the two groups (OR 5.22; 95% 0.62–44.24; p < 0.13; I 2 = 85%). Menstrual irregularities (OR 1.09; 95% 0.37–3.25; p = 0.88; I 2 = 33%) and breast enlargement (OR 1.37; 95% 0.79–2.38; p = 0.26; I 2 = 0%) were nonsignificant in patients taking spironolactone. Trial sequential analysis (TSA) confirmed that the required sample size was reached, favoring spironolactone over placebo.
Conclusion
Our study suggests that oral spironolactone improves acne in female patients compared to placebo without increasing risks; thus, it should be elevated from “off‐label” use to an officially recommended standard of care. PROSPERO Registration CRD42024626984.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
- Dow Medical College, Karachi, Pakistan.
- Universidad de los Andes, Bogotá, Colombia.
- Universidad San Francisco de Quito, Quito, Ecuador.
- Pontificia Universidad Javeriana, Bogotá, Colombia.
- Dermatology Department, University of Virginia, Charlottesville, Virginia, USA.
ORCID-Profile: Laura Ghanem, Najwaa Kirmani, Nathalia De León Fernández, María Paula Palacios-Ortiz, Juan David Rodríguez-Parra, Corina A Rusu
Zitieren
APA
Ghanem, L., Kirmani, N., De León Fernández, N., Palacios-Ortiz, M. P., Rodríguez-Parra, J. D., & Rusu, C. A. (2025). Efficacy and Safety of Oral Spironolactone for Women With Acne Vulgaris: A Systematic Review and Meta‐Analysis of Randomized Placebo‐Controlled Trials With Trial Sequential Analysis. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70411
Vancouver
Ghanem L, Kirmani N, De León Fernández N, Palacios-Ortiz MP, Rodríguez-Parra JD, Rusu CA. Efficacy and Safety of Oral Spironolactone for Women With Acne Vulgaris: A Systematic Review and Meta‐Analysis of Randomized Placebo‐Controlled Trials With Trial Sequential Analysis. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70411
BibTeX
@article{Ghanem2025,
author = {Ghanem, Laura and Kirmani, Najwaa and De León Fernández, Nathalia and Palacios-Ortiz, María Paula and Rodríguez-Parra, Juan David and Rusu, Corina A},
title = {Efficacy and Safety of Oral Spironolactone for Women With Acne Vulgaris: A Systematic Review and Meta‐Analysis of Randomized Placebo‐Controlled Trials With Trial Sequential Analysis},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.70411}
}
EUVIMED